ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IRON Disc Medicine Inc

34.28
0.93 (2.79%)
25 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Disc Medicine Inc NASDAQ:IRON NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.93 2.79% 34.28 31.35 38.84 34.92 31.60 33.20 565,684 05:00:12

Disc Medicine to Participate in Upcoming Investor Conferences

08/11/2023 9:30pm

GlobeNewswire Inc.


Disc Medicine (NASDAQ:IRON)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Disc Medicine Charts.

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at the Stifel 2023 Healthcare Conference on Wednesday, November 15th at 11:30 am ET. Disc will also give presentations at the Jefferies London Healthcare Conference on Thursday, November 16th at 9:30 am GMT / 4:30 am ET and the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30th at 2:30 pm ET.

A live webcast of the presentations will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.

About Disc

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg RusconiVerge Scientific Communicationsprusconi@vergescientific.comĀ 

Investor Relations Contact

Christina TartagliaStern Investor Relationschristina.tartaglia@sternir.comĀ 

1 Year Disc Medicine Chart

1 Year Disc Medicine Chart

1 Month Disc Medicine Chart

1 Month Disc Medicine Chart